Company
Sydney, NSW
Every investor coverage indicates participated in a round Kazia Therapeutics Limited raised.
Companies Kazia Therapeutics Limited acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Kazia Therapeutics Limited. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Kazia Therapeutics reviews its 2019 clinical trial data read-outs at its AGM and recalls a share placement that strengthened its balance sheet and brought new institutional investors onto its register.
Cancer drug developer Kazia pitched to AusBiotech Invest, highlighting its Genentech-designed brain cancer candidate GDC-0084, ongoing trials, and solid finances after a recent institutional placement.
Kazia Therapeutics' chief executive discussed the biotech's recent four-million-dollar raise, ovarian cancer trial data, and a trans-Tasman award win during an interview in CommSec's executive series.
Kazia Therapeutics confirmed it received an R&D tax rebate from the Australian Taxation Office for the 2018 financial year, with funds earmarked for its clinical programs.